Ashok Ananda Hajare
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashok Ananda Hajare has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Kiran S. Patil
Department of Pharmaceutical Quality Assurance, Tatyasaheb Kore College of Pharmacy, Shivaji University, Warananagar, Kolhapur, India
7 shared publications Arehalli S. Manjappa
2 shared publications- Harinath N. More
Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy, Kolhapur, India
2 shared publications Hemalata S. Dol
2 shared publicationsKiran S. Patil
Department of Pharmaceutical Quality Assurance, Tatyasaheb Kore College of Pharmacy, Warnanagar, Kolhapur - 416113, Maharashtra
2 shared publicationsPriyanka B. Varne
Bharati Vidyapeeth College of Pharmacy, Kolhapur, Maharashtra, India 416013
2 shared publications
Latest Publications
- 1 September 2026
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 19 (9) , 4369-4378
Microemulsion-Mediated Abiraterone Acetate Nanoparticles: Formulation and Optimization
The BCS Class IV drug abiraterone acetate (ABR) exhibits biopharmaceutical difficulties including polymorphism, poor solubility (< 0.5 µg/mL), variable permeability, and low oral bioavailability (<10 %, necessitating a large dose of 1000 mg/day). The primary goal of the current study is to produce solid lipid nanoparticles (SLNs) that are loaded with ABR to improve solubility. SLNs were manufactured by O/W microemulsion method. Initial screening of lipids was done by solubility study whereas surfactants and co-surfactants were selected on the basis of their HLB values. Based on preformulation studies, Myristic acid, Tween 80 and PEG 400 were selected for SLN composition. Using Central Composite Design (CCD) experiments were conducted to optimize the composition using concentration of solid lipid and S-mix as independent variables while particle size, entrapment efficiency (EE), and zeta potential as independent variables. Optimized SLN formulation and pure drug were compared for in vitro drug release. Cytotoxicity study of optimized formulation was tested using MTT assay method. The statistical evaluation confirmed that optimized ABR-SLNs were spherical with average size of 194.26 nm, polydispersity index (PDI) of 0.491, EE of 89.56 %, and zeta potential of -23.77 mV. Drug release from optimized formulation over 6 h and cytotoxicity study demonstrated remarkable anticancer activity. It was observed that SLN shows significant improvement in the solubility of ABR. Hence, SLN can acts as drug delivery system for enhancing the solubility of poorly soluble drugs.
- 1 September 2026
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 19 (9) , 4369-4378
Microemulsion-Mediated Abiraterone Acetate Nanoparticles: Formulation and Optimization
The BCS Class IV drug abiraterone acetate (ABR) exhibits biopharmaceutical difficulties including polymorphism, poor solubility (< 0.5 µg/mL), variable permeability, and low oral bioavailability (<10 %, necessitating a large dose of 1000 mg/day). The primary goal of the current study is to produce solid lipid nanoparticles (SLNs) that are loaded with ABR to improve solubility. SLNs were manufactured by O/W microemulsion method. Initial screening of lipids was done by solubility study whereas surfactants and co-surfactants were selected on the basis of their HLB values. Based on preformulation studies, Myristic acid, Tween 80 and PEG 400 were selected for SLN composition. Using Central Composite Design (CCD) experiments were conducted to optimize the composition using concentration of solid lipid and S-mix as independent variables while particle size, entrapment efficiency (EE), and zeta potential as independent variables. Optimized SLN formulation and pure drug were compared for in vitro drug release. Cytotoxicity study of optimized formulation was tested using MTT assay method. The statistical evaluation confirmed that optimized ABR-SLNs were spherical with average size of 194.26 nm, polydispersity index (PDI) of 0.491, EE of 89.56 %, and zeta potential of -23.77 mV. Drug release from optimized formulation over 6 h and cytotoxicity study demonstrated remarkable anticancer activity. It was observed that SLN shows significant improvement in the solubility of ABR. Hence, SLN can acts as drug delivery system for enhancing the solubility of poorly soluble drugs.
- 31 August 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1) , 127
Electrospun Polymeric Nanofibrous Blend for Improved Oral Sertraline Dissolution: Fabrication, In Vitro Evaluation, and In Vivo Assessment
- 31 August 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1) , 127
Electrospun Polymeric Nanofibrous Blend for Improved Oral Sertraline Dissolution: Fabrication, In Vitro Evaluation, and In Vivo Assessment
- 24 September 2024
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 17 (9) , 4262-4266
Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Dasatinib in Bulk and Niosomal Formulation
The accurate, fast, cost effective RP- HPLC chromatographic method was developed and validated as per the ICH guidelines, for linearity, accuracy, interday-intraday precision, specificity and selectivity, robustness, solution stability. Current study is focused on the method development of dasatinib (DS) which is having anticancer activity by inhibiting tyrosine kinase enzyme. Standard curve of DS was constructed in methanol at λmax 325 nm using UV spectroscope. For RP-HPLC method development mobile phase used was acetonitrile: Potassium dihydrogen phosphate buffer in the ratio 60:40 %v/v, with flow rate of 1 mL/min at a temperature of 30 ℃. Maximum wavelength 325 nm were selected for the analysis of DS. The linearity of the solution was detected at 325 nm within the concentration range from 20 -120 µg/mL with a correlation value (R2) of 0.999975 indicating a very strong relationship between dependent and independent variables suggesting the accuracy of the method selected. The concentration of DS in niosomes was determined by the currently developed method. Validation parameters were used to evaluate, specificity, linearity, sensitivity, accuracy, precision, and ruggedness. About 98-102 (%v/v) of DS was found to be within standard limits and compliant with the standards set by the International Council of Harmonization (ICH) demonstrating the accuracy of the method used. The RP-HPLC method is more sensitive, accurate and precise compared to the previously reported method. There was no interference of excipients in the recovery study. The low value of %RSD was suggested that the developed method is sensitive. The proposed reverse phase high performance liquid chromatographic method proved to be convenient, simple and effective for the quality control of DS.
- 24 September 2024
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 17 (9) , 4262-4266
Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Dasatinib in Bulk and Niosomal Formulation
The accurate, fast, cost effective RP- HPLC chromatographic method was developed and validated as per the ICH guidelines, for linearity, accuracy, interday-intraday precision, specificity and selectivity, robustness, solution stability. Current study is focused on the method development of dasatinib (DS) which is having anticancer activity by inhibiting tyrosine kinase enzyme. Standard curve of DS was constructed in methanol at λmax 325 nm using UV spectroscope. For RP-HPLC method development mobile phase used was acetonitrile: Potassium dihydrogen phosphate buffer in the ratio 60:40 %v/v, with flow rate of 1 mL/min at a temperature of 30 ℃. Maximum wavelength 325 nm were selected for the analysis of DS. The linearity of the solution was detected at 325 nm within the concentration range from 20 -120 µg/mL with a correlation value (R2) of 0.999975 indicating a very strong relationship between dependent and independent variables suggesting the accuracy of the method selected. The concentration of DS in niosomes was determined by the currently developed method. Validation parameters were used to evaluate, specificity, linearity, sensitivity, accuracy, precision, and ruggedness. About 98-102 (%v/v) of DS was found to be within standard limits and compliant with the standards set by the International Council of Harmonization (ICH) demonstrating the accuracy of the method used. The RP-HPLC method is more sensitive, accurate and precise compared to the previously reported method. There was no interference of excipients in the recovery study. The low value of %RSD was suggested that the developed method is sensitive. The proposed reverse phase high performance liquid chromatographic method proved to be convenient, simple and effective for the quality control of DS.
- Open Access
- 1 January 2024
- Published by Indian Pharmaceutical Association - IPA
- Vol. 86 (2) , 660-666
Exploring Cosolvency in Analytical Method Development and Validation of Poorly Aqueous Soluble Candesartan Cilexetil in Bulk and Dosage Forms
The study was performed with a dual approach to develop and validate analytical method for poorly water soluble candesartan cilexetil by enhancing its solubility employing cosolvency technique. In order to enhance drug’s solubility based on its solubility characteristics, phosphate buffer (pH 6.8):ethanol (95 % v/v) mixture at 90:10 proportion was used along with Tween 80 (1 % v/v). Solubility of candesartan cilexetil in phosphate buffer (pH 6.8) enhanced due to the addition of co-solvent ethanol and Tween 80. Developed method obeyed Beer-Lambert’s law in the concentration range between 3-21 μg/ml. The regression coefficient at the wavelength 232 nm was 0.999. The analysis of tablets by the proposed method indicated a good correlation between estimated and label claims. Recovery studies showed that any small difference in drug concentration could be accurately determined. Low values of limit of detection and limit of quantitation indicated that the proposed method is sensitive, economic, accurate, precise, and robust for routine analysis of candesartan cilexetil in bulk and dosage forms.
- 1 January 2024
- Published by Indian Pharmaceutical Association - IPA
- Vol. 86 (2) , 660-666
Open AccessExploring Cosolvency in Analytical Method Development and Validation of Poorly Aqueous Soluble Candesartan Cilexetil in Bulk and Dosage Forms
The study was performed with a dual approach to develop and validate analytical method for poorly water soluble candesartan cilexetil by enhancing its solubility employing cosolvency technique. In order to enhance drug’s solubility based on its solubility characteristics, phosphate buffer (pH 6.8):ethanol (95 % v/v) mixture at 90:10 proportion was used along with Tween 80 (1 % v/v). Solubility of candesartan cilexetil in phosphate buffer (pH 6.8) enhanced due to the addition of co-solvent ethanol and Tween 80. Developed method obeyed Beer-Lambert’s law in the concentration range between 3-21 μg/ml. The regression coefficient at the wavelength 232 nm was 0.999. The analysis of tablets by the proposed method indicated a good correlation between estimated and label claims. Recovery studies showed that any small difference in drug concentration could be accurately determined. Low values of limit of detection and limit of quantitation indicated that the proposed method is sensitive, economic, accurate, precise, and robust for routine analysis of candesartan cilexetil in bulk and dosage forms.
- Open Access
- 27 December 2023
- Published by FABAD Farmasotik Bilimler Ankara Dernegi in Fabad Journal of Pharmaceutical Sciences
- Vol. 49 (1) , 143-162
Design, Development, and Characterization of Lyophilized Posaconazole-Loaded Mixed Micelles for Improved Fungal Treatment and Stability
Posaconazole, a BCS class II drug with poor solubility, hampers its absorption in the body, leading to suboptimal drug levels and reduced treatment effectiveness. To address this issue, this research aimed to develop a lyophilized powder of posaconazole-loaded mixed micelles (POS-MMs) using pluronic F68 and soluplus to enhance fungal treatment and stability. A 32 factorial design optimized the POS-MMs formulation by varying PF68 and soluplus concentrations. Various characterization techniques were employed, including particle size analysis, zeta potential measurement, FTIR, DSC, and XRPD. In vitro drug release studies indicated sustained release with 79.4% released within 24 hrs, while in vitro hemolysis studies confirmed biocompatibility. Lyophilization with lactose as a cryoprotectant was successful, yielding a stable formulation over three months. The optimized POS-MMs exhibited a particle size of 66.30 ± 2.10 nm, a high % entrapment efficiency of 94.88 ± 2.4%, and a desirable zeta potential of -25.3±2.8 mV. These findings highlight the potential of POS-MMs to enhance the therapeutic outcomes of posaconazole in the treatment of fungal infections. In addition, lyophilized powder is a promising technique for improving the stability of POS-MMs.
- 27 December 2023
- Published by FABAD Farmasotik Bilimler Ankara Dernegi in Fabad Journal of Pharmaceutical Sciences
- Vol. 49 (1) , 143-162
Open AccessDesign, Development, and Characterization of Lyophilized Posaconazole-Loaded Mixed Micelles for Improved Fungal Treatment and Stability
Posaconazole, a BCS class II drug with poor solubility, hampers its absorption in the body, leading to suboptimal drug levels and reduced treatment effectiveness. To address this issue, this research aimed to develop a lyophilized powder of posaconazole-loaded mixed micelles (POS-MMs) using pluronic F68 and soluplus to enhance fungal treatment and stability. A 32 factorial design optimized the POS-MMs formulation by varying PF68 and soluplus concentrations. Various characterization techniques were employed, including particle size analysis, zeta potential measurement, FTIR, DSC, and XRPD. In vitro drug release studies indicated sustained release with 79.4% released within 24 hrs, while in vitro hemolysis studies confirmed biocompatibility. Lyophilization with lactose as a cryoprotectant was successful, yielding a stable formulation over three months. The optimized POS-MMs exhibited a particle size of 66.30 ± 2.10 nm, a high % entrapment efficiency of 94.88 ± 2.4%, and a desirable zeta potential of -25.3±2.8 mV. These findings highlight the potential of POS-MMs to enhance the therapeutic outcomes of posaconazole in the treatment of fungal infections. In addition, lyophilized powder is a promising technique for improving the stability of POS-MMs.
- 27 April 2023
- Published by Taylor & Francis in Journal of Dispersion Science and Technology
- Vol. 45 (6) , 1227-1240
Development of Doxazosin mesylate liquisolid system for improved manufacturing processability and bioavailability: in vitro and in vivo evaluation for tailored hypertension treatment approach with modified dissolution rates
In the present research, an attempt was made to optimize the blends of different carriers Neusiln US2, Avicel PH101, and Fujicalin SG by individually blending with each of coating materials Aerosil 200 and Syloid 244 FP that were proposed to contribute to a modified drug dissolution rates of Doxazosin mesylate (DX) through a liquisolid polymer matrix system. The liquisolid formulations were prepared using selected solvent, carriers, and coats by varying drug to polymer ratios. Further formulations were investigated for pre-compression processability by Heckel plot analysis, elastic recovery studies, and post-compression characteristics. In case of carriers, compared to Avicel PH101 highest flowable values (ф) were observed for Neusilin US2 and Fujicalin SG whereas, for coat these values were highest for Aerosil 200 than Sylloid 244 FP. Liquisolid compact with Fujicalin SG and Aerosil 200 exhibited fast release (FR) of 78% in 20 minutes. The liquisolid compact with Neusilin US2 and Syloid 244 FP exhibited prolonged release (PR) of 60% in 240 minutes. DSC and XRD analysis showed loss of DX crystallinity which was confirmed by SEM analysis indicating DX detention within the liquisolid system, in a molecularly dispersed solubilized form. The in vivo studies of DX liquisolid FR formulation exhibited 1.89 fold increase in the oral bioavailability which was 1.69 fold for DX PR formulation compared to pure DX which demonstrated a promising tailored hypertension treatment approach. Graphical abstract
- 27 April 2023
- Published by Taylor & Francis in Journal of Dispersion Science and Technology
- Vol. 45 (6) , 1227-1240
Development of Doxazosin mesylate liquisolid system for improved manufacturing processability and bioavailability: in vitro and in vivo evaluation for tailored hypertension treatment approach with modified dissolution rates
In the present research, an attempt was made to optimize the blends of different carriers Neusiln US2, Avicel PH101, and Fujicalin SG by individually blending with each of coating materials Aerosil 200 and Syloid 244 FP that were proposed to contribute to a modified drug dissolution rates of Doxazosin mesylate (DX) through a liquisolid polymer matrix system. The liquisolid formulations were prepared using selected solvent, carriers, and coats by varying drug to polymer ratios. Further formulations were investigated for pre-compression processability by Heckel plot analysis, elastic recovery studies, and post-compression characteristics. In case of carriers, compared to Avicel PH101 highest flowable values (ф) were observed for Neusilin US2 and Fujicalin SG whereas, for coat these values were highest for Aerosil 200 than Sylloid 244 FP. Liquisolid compact with Fujicalin SG and Aerosil 200 exhibited fast release (FR) of 78% in 20 minutes. The liquisolid compact with Neusilin US2 and Syloid 244 FP exhibited prolonged release (PR) of 60% in 240 minutes. DSC and XRD analysis showed loss of DX crystallinity which was confirmed by SEM analysis indicating DX detention within the liquisolid system, in a molecularly dispersed solubilized form. The in vivo studies of DX liquisolid FR formulation exhibited 1.89 fold increase in the oral bioavailability which was 1.69 fold for DX PR formulation compared to pure DX which demonstrated a promising tailored hypertension treatment approach. Graphical abstract
- 28 September 2022
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 15 (9) , 4248-4252
Development and validation of RP-HPLC method for estimation of camptothecin in mixed micelle formulation
Camptothecin is a potent anticancer agent. Numerous studies on camptothecin had been reported in the literature; here an effort is made to develop a new HPLC method for camptothecin estimation in pharmaceutical dosage forms that will be accurate, simple, and sensitive. A fast, simple, and accurate spectrophotometric technique for the quantitative measurement of Camptothecin in active pharmaceutical components and pharmaceutical dosage formulations has been developed and validated. An RP-HPLC method was devised using Acetonitrile: Water (90:10) as the mobile phase, 1mL/min flow rate, and the temperature of 30 ℃. The linearity was observed in the concentration range of 20-100 μg/ml with maximum wavelength of 219 nm and a correlation value (R2) of 0.9995. The current method was used to determine the concentration of camptothecin in mixed micelles containing camptothecin, PF108, and TPGS. The suggested method's accuracy, precision, sensitivity, and ruggedness were evaluated using validation parameters. Recovery of camptothecin was found to be in the range of 98–102%, indicating that the developed method is accurate. The accuracy and robustness were found to be within acceptable limits and in compliance with ICH standards. This method can be used for routine analysis of camptothecin of pharmaceutical formulation in any pharmaceutical dosage form.
- 28 September 2022
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 15 (9) , 4248-4252
Development and validation of RP-HPLC method for estimation of camptothecin in mixed micelle formulation
Camptothecin is a potent anticancer agent. Numerous studies on camptothecin had been reported in the literature; here an effort is made to develop a new HPLC method for camptothecin estimation in pharmaceutical dosage forms that will be accurate, simple, and sensitive. A fast, simple, and accurate spectrophotometric technique for the quantitative measurement of Camptothecin in active pharmaceutical components and pharmaceutical dosage formulations has been developed and validated. An RP-HPLC method was devised using Acetonitrile: Water (90:10) as the mobile phase, 1mL/min flow rate, and the temperature of 30 ℃. The linearity was observed in the concentration range of 20-100 μg/ml with maximum wavelength of 219 nm and a correlation value (R2) of 0.9995. The current method was used to determine the concentration of camptothecin in mixed micelles containing camptothecin, PF108, and TPGS. The suggested method's accuracy, precision, sensitivity, and ruggedness were evaluated using validation parameters. Recovery of camptothecin was found to be in the range of 98–102%, indicating that the developed method is accurate. The accuracy and robustness were found to be within acceptable limits and in compliance with ICH standards. This method can be used for routine analysis of camptothecin of pharmaceutical formulation in any pharmaceutical dosage form.